In CF, the first phase II clinical trials have shown the absence of toxicity and good tolerance of these therapies, but without clinical efficacy; the administration frequency to optimize the quantity of CFTR proteins at the membrane is still to be determined. Here, CFTR is linked to cystic fibrosis.